Please ensure Javascript is enabled for purposes of website accessibility

MediPharm Ships Its First Batch of Cannabis Topicals

By Eric Volkman - Mar 26, 2020 at 11:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company says it will accelerate its R&D for such products.

Cannabis products maker MediPharm Labs (MEDIF 8.35%) has added another category to its lineup: On Wednesday, it announced that it had made its first shipment of bottled cannabis topicals. 

In this case, MediPharm is acting as a contract manufacturer for another company, which it did not identify. The topicals, produced at MediPharm's processing facility in Barrie, Ontario, will ultimately be sold as for both medical and recreational use.

This apparently is only the beginning. In the press release announcing the shipment, MediPharm said that it's accelerating its research and development activities around topicals. It did not, however, provide any details about how much capital it intended to devote to this ramped-up effort.

Jar of cream with cannabis leaf.

Image source: Getty Images

"Following Cannabis 2.0 legalization in Canada, it's clear there is demand for cannabis topicals," the company said. "We also expect worldwide demand for topicals could increase as new cannabis markets start to come online and legalize concentrate based products."

Cannabis 2.0 refers to the second phase of recreational-use legalization in Canada, which sanctioned the production and sale of cannabis derivative products like edibles and topicals. Although it officially began late last year, marijuana companies have only recently begun shipping and selling such goods. 

MediPharm is a cannabis company that specializes in extraction and related services. It is active in markets abroad; earlier this month, the company announced its subsidiary in Australia signed a contract manufacturing agreement to supply cannabis oil products.

Investors were apparently heartened by the news. They bid MediPharm's shares up by over 7% on Wednesday, a figure that exceeded the gains of the key U.S. stock market indexes on the day.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
$0.07 (8.35%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.